Evaluating Monoclonal Gammopathy of Undetermiend Significance (MGUS) with Free Light Chain Assays...

Presented By:
Dr. John V. Mitsios
Speaker Biography:
Dr. Mitsios graduated from the University of Ioannina, Greece with a PhD in Chemistry. Upon completion of his doctoral thesis, he then went on to complete a post-doctoral fellowship at the University of California, San Diego. Dr. Mitsios then transitioned to the world of Clinical Chemistry and completed a fellowship at Washington University in St. Louis, MO. His primary research interest throughout his education and training has been in coagulation, with an emphasis on platelet function and biology. Dr. Mitsios joined Siemens-Healthineers as a clinical consultant as part of the Scientific and Clinical Affairs team. In addition, Dr. Mitsios has co-authored 20 peer-reviewed articles and 3 book chapters.
Webinar:
Evaluating Monoclonal Gammopathy of Undetermiend Significance (MGUS) with Free Light Chain Assays in Clinical Practice
Webinar Abstract:
Multiple myeloma is a cancer of the plasma cell. Plasma cells are white blood cells that make antibodies that help to protect us from infections. However, the cells grow too much in myeloma, crowding out normal cells in the bone marrow that make red blood cells, platelets, and other white blood cells. The purpose of today’s presentation will be to discuss the pathophysiology of multiple myeloma with an emphasis on monoclonal gammopathy of undetermined significance (MGUS). Specifically, the presentation is designed for laboratorians/clinicians who are interested in learning more about the clinical and laboratory investigation of multiple myeloma and MGUS.
LabRoots on Social:
Facebook: / labrootsinc
Twitter: / labroots
LinkedIn: / labroots
Instagram: / labrootsinc
Pinterest: / labroots
SnapChat: labroots_inc

[@DellAnderson]

It is not clear whether the N Latex Free Light Chain (Siemens FLC) is FDA cleared for anything but MGUS monitoring. SMM progression to MM was discussed but it wasn't clearly stated that FDA approved this particular test for this purpose. Can you please clarify?
Also, how does a physician (or patient) verify which test was performed and where? Must we really call the laboratory each time? Given the importance as a tumor marker, and the need for duplicate testing when changing labs/vendors (as is often the case when traveling, changing insurance, or just adapting to 'cheapest bidder' hospital practices, this puts a huge burden on physicians and patients that few appreciate enough to follow-up I suspect.